[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, Sotatercept has been shown to be effective for the treatment of Pulmonary Arterial Hypertension. Document [0] states that 24 weeks of Sotatercept resulted in a significantly greater reduction in pulmonary vascular resistance compared to placebo. Document [1] also confirms that Sotatercept reduced pulmonary vascular resistance and improved exercise tolerance in patients with PAH. Additionally, Document [8] mentions that Sotatercept reduced pulmonary vascular resistance and improved hemoglobin concentration in patients with PAH. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]